Glycated albumin (GA) is more advantageous than hemoglobin a1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetes

Internal Medicine

Volumn 53, Issue 8, 2014, Pages 829-835

  Shima, Kenji ^a   Komatsu, Machiko ^a   Noma, Yoshihiko ^a   Miya, Keiko ^a  

^a Kawashima Hospital   (Japan)

Author keywords

Glycated albumin; Hemoglobin A1c; Sitagliptin; Type 2 diabetes

Indexed keywords

GLICLAZIDE; GLIMEPIRIDE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED SERUM ALBUMIN; PYRAZINE DERIVATIVE; SERUM ALBUMIN; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; AUTOANALYZER; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PYRAZINES; SERUM ALBUMIN; TRIAZOLES;

EID: 84898665597     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.53.1364     Document Type: Article

References (21)

1. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 79: 291-298, 2008.
2. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus. Endocr J 57: 383-394, 2010.
3. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 18: 440-447, 1995.
4. Day JF, Ingebretsen CG, Ingebretsen WR, Baynes JW, Thorpe SR. Nonenzymatic glycosylation of serum protein and hemoglobin: response to changes in blood glucose levels in diabetic rats. Diabetes 29: 524-527, 1980.
5. Iberg N, Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem 261: 13542-13545, 1986.
6. Sawa T, Ohta A, Matsui T, et al. Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGMS). Endocr J 57: 135-140, 2010.
7. Tsutsumi C, Imagawa N, Onishi M, et al. Glycated albumina as a useful clinical biomarker for glycemic variability in type 1 diabetes assessed by continuous glucose monitoring. Diabetol Int 4: 156-159, 2013.
8. Ahren B, Landin-Olsson M, Jonsson P-A, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89: 2078-2084, 2004.
9. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91: 4612-4619, 2006.
10. Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 43: 13-25, 2007.
11. Hamaguchi T, Koga M, Murai J, et al. Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks. J Diabetes Investig 3: 175-178, 2012.
12. Kozuma T, Usami T, Yamakoshi M, Takahashi M, Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta 324: 61-71, 2002.
13. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 83: 233-240, 2009.
14. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 58: 69-73, 2011.
15. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 26 (Suppl 1): S33-S50, 2003.
16. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28: 1556-1568, 2006.
17. Charbbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes in adequately controlled with metformin alone. Diabetes Care 29: 2638-2643, 2006.
18. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl-peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferior trial. Diabetes Obes Metab 9: 194-205, 2007.
19. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control inpatients with type 2 diabetes. Diabetes Care 30: 1979-1987, 2007.
20. Ito M, Abe M, Okada K, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 58: 979-987, 2011.
21. Kume S, Uzu T, Takagi C, et al. Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis. J Diabetes Investig 3: 298-301, 2012.